Trovagene, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2012. The supplied filing is for Trovagene, Inc., not Cardiff Oncology, Inc. Trovagene describes itself as a development-stage molecular diagnostics company developing urine-based nucleic acid tests. It reported minimal licensing revenue and no commercial products.
Financial performance and position
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $34,153 | $89,082 |
| Research and development expense | $337,407 | $258,016 |
| General and administrative expense | $826,964 | $551,044 |
| Operating loss | $1,130,218 | $719,978 |
| Net loss | $1,162,642 | $551,987 |
| Net loss attributable to common stockholders | $1,172,202 | $561,547 |
| Net cash used in operating activities | $905,088 | $568,653 |
- Revenue fell by $54,929, reflecting lower royalties and no Q1 2012 license fees. Royalty income was $34,153; the comparable period included $20,000 of license fees.
- Cash and cash equivalents were $586,777 at March 31, down from $700,374 at year-end. The company reported a working-capital deficit of $826,997 and total assets of $1.18 million against total liabilities of $5.52 million.
- Derivative financial instrument liabilities were $3.98 million, measured using significant unobservable inputs (Level 3). Stockholders’ deficiency was $4.33 million. No interest expense was recorded in Q1 2012; convertible debentures had been extinguished in July 2011.
- Q1 financing provided $889,500, primarily from common-stock sales; investing used $98,009, mainly for capital equipment and intangible assets. The filing reports cumulative development-stage losses of $44.77 million.
Material changes and developments
- Net loss more than doubled year over year. R&D expense increased by $79,391, mainly following startup of CLIA laboratory operations; G&A increased by $275,920, including higher outside services and legal and accounting fees.
- On February 1, 2012, Trovagene acquired a CLIA license from MultiGen Diagnostics for 750,000 shares valued at $187,500. Up to a further $3.7 million could be payable in cash and/or stock if specified sales and earnings targets are met; the filing assigned the contingent consideration a fair value of zero at acquisition.
- Q1 private placements raised $950,000 gross. Subsequent placements raised $650,000 on April 13 and $300,000 on May 2. The filing also reports a reverse-stock-split authorization of 1-for-2 to 1-for-6, exercisable by the board before April 27, 2013; it had not occurred by the filing date.
- Common shares outstanding were 67,146,857 at March 31 and 69,180,357 as of May 14, 2012. The company also approved increasing the stock option plan reserve from 12 million to 22 million shares and authorized an increase in common shares from 100 million to 150 million.
Outlook, risks and controls
- Going concern: Management said additional capital was needed to fund operations and development. The filing reports approximately $823,000 in bank cash at May 11 and projected funds sufficient to pay expenses through July 2012. It also says additional capital would be required within the next year.
- Further funding was not assured. Failure to obtain it could force delays, reductions or discontinuation of development or commercialization, earlier and less favorable partnerships, or disposal of technology and product rights. Equity financing could dilute shareholders; debt financing could impose restrictive covenants.
- Management expected continued operating cash outflows for several years and stated that commercial products were not expected for several years, if at all. The filing provides no quantified revenue or earnings guidance.
- The company corrected an approximately $275,000 error in derivative-liability accounting; it stated the correction’s effect on Q1 operations was de minimis. Derivative fair-value changes contributed a $32,424 loss in Q1.
- Management concluded disclosure controls and procedures were ineffective because of weaknesses in the financial closing process and said it intended to implement remedial measures. No material change in internal control over financial reporting was reported during the quarter.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
Investor verification priorities
- Confirm the company and filing identity: the supplied 10-Q is Trovagene, Inc., despite the request metadata naming Cardiff Oncology.
- Verify near-term liquidity, actual cash runway, and the timing and terms of any further financing, including dilution and warrant effects.
- Reconcile the filing’s inconsistent May 2 financing descriptions: one passage reports warrants for 1.3 million shares, while another reports 600,000 warrants.
- Review the valuation and accounting of price-protected warrants and other Level 3 derivative liabilities, including the disclosed correction.
- Assess progress, costs and commercialization prospects for the CLIA laboratory and acquired license, and the conditions attached to the potential $3.7 million contingent payment.
- Track remediation of the financial-close control weakness and execution of the authorized share-count, option-plan and reverse-split changes.